Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Parecoxib
Drug ID BADD_D01674
Description Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. A letter of non-approval for parecoxib was issued by the FDA in 2005.
Indications and Usage Used for short term perioperative pain control.
Marketing Status approved
ATC Code M01AH04
DrugBank ID DB08439
KEGG ID D03716
MeSH ID C409945
PubChem ID 119828
TTD Drug ID D05UWI
NDC Product Code Not Available
UNII 9TUW81Y3CE
Synonyms parecoxib | N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamide | N-(((Me-P)-P)S)P | parecoxib sodium | N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamine, sodium salt | Dynastat
Chemical Information
Molecular Formula C19H18N2O4S
CAS Registry Number 198470-84-7
SMILES CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation17.02.05.012; 19.06.02.001--
Alanine aminotransferase increased13.03.04.005--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Bradycardia02.03.02.002--Not Available
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac failure congestive02.05.01.002--Not Available
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Constipation07.02.02.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Ear disorder04.03.01.001--Not Available
Ear pain04.03.01.003--
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Flatulence07.01.04.002--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages